Pharming Group (OTCMKTS:PHGUF) Hits New 1-Year High – Still a Buy?

Pharming Group NV (OTCMKTS:PHGUF)’s stock price reached a new 52-week high on Friday . The stock traded as high as $1.65 and last traded at $1.65, with a volume of 5000 shares changing hands. The stock had previously closed at $1.53.

Pharming Group Trading Up 7.8%

The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.07 and a current ratio of 2.79. The firm has a market capitalization of $1.11 billion, a PE ratio of 165.00 and a beta of 0.61. The stock’s 50-day simple moving average is $1.50 and its 200-day simple moving average is $1.27.

Pharming Group (OTCMKTS:PHGUF) last announced its earnings results on Thursday, November 6th. The biotechnology company reported $0.01 earnings per share for the quarter. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $97.30 million for the quarter, compared to analyst estimates of $80.18 million.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.